These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6913607)

  • 1. Purification from guinea pig erythrocyte stroma of a decay-accelerating factor for the classical c3 convertase, C4b,2a.
    Nicholson-Weller A; Burge J; Austen KF
    J Immunol; 1981 Nov; 127(5):2035-9. PubMed ID: 6913607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation of C4-binding protein from guinea pig plasma and demonstration of its function as a control protein of the classical complement pathway C3 convertase.
    Burge J; Nicholson-Weller A; Austen KF
    J Immunol; 1981 Jan; 126(1):232-5. PubMed ID: 6778916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.
    Nicholson-Weller A; Burge J; Fearon DT; Weller PF; Austen KF
    J Immunol; 1982 Jul; 129(1):184-9. PubMed ID: 6211481
    [No Abstract]   [Full Text] [Related]  

  • 5. Murine membrane inhibitor of complement which accelerates decay of human C3 convertase.
    Kameyoshi Y; Matsushita M; Okada H
    Immunology; 1989 Dec; 68(4):439-44. PubMed ID: 2481641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    Medof ME; Kinoshita T; Nussenzweig V
    J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
    Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
    J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation and deregulation of the fluid-phase classical pathway C3 convertase.
    Gigli I; Sorvillo J; Halbwachs-Mecarelli L
    J Immunol; 1985 Jul; 135(1):440-4. PubMed ID: 3158705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase.
    Gigli I; Sorvillo J; Mecarelli-Halbwachs L; Leibowitch J
    J Exp Med; 1981 Jul; 154(1):1-12. PubMed ID: 7019379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes.
    Kinoshita T; Medof ME; Nussenzweig V
    J Immunol; 1986 May; 136(9):3390-5. PubMed ID: 2420889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification and characterization of decay-accelerating factor (DAF) from Raji cells.
    Fujita T; Shinkai Y; Inoue T; Tamura N
    Immunology; 1988 Jul; 64(3):369-74. PubMed ID: 2457546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular basis for the difference in immune hemolysis activity of the Chido and Rodgers isotypes of human complement component C4.
    Isenman DE; Young JR
    J Immunol; 1984 Jun; 132(6):3019-27. PubMed ID: 6609966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional forms of human decay-accelerating factor (DAF).
    Seya T; Farries T; Nickells M; Atkinson JP
    J Immunol; 1987 Aug; 139(4):1260-7. PubMed ID: 2440950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein.
    Daha MR; van Es LA
    J Immunol; 1980 Nov; 125(5):2051-4. PubMed ID: 6903579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptors on guinea-pig erythrocytes specific for cell-bound fourth component of human complement (C4).
    Wilson AB; Prichard-Thomas S; Lachmann PJ; Coombs RR
    Immunology; 1980 Feb; 39(2):195-202. PubMed ID: 7380467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
    Iwata K; Seya T; Ariga H; Nagasawa S
    J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of the classical pathway C3 convertase (EAC4b2a) by proteolytic enzymes.
    Loos M; Heinz HP
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():67-74. PubMed ID: 6375257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A monoclonal antibody that blocks the complement regulatory activity of guinea pig erythrocytes and characterization of the antigen involved as guinea pig decay-accelerating factor.
    Okada N; Tanaka H; Takizawa H; Okada H
    J Immunol; 1995 Jun; 154(11):6103-11. PubMed ID: 7538542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.